Nabi Biopharmaceuticals
(Public, NASDAQ:NABI) Watch this stockFind more results for
NABI
Advertisement
Events
Nov 5, 2009
Q3 2009 Earnings Conference Call -
Nov 5, 2009
Q3 2009 Earnings Release
Sep 10, 2009
Rodman & Renshaw Annual Global Investment Conference
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -24.32% | -7.82% |
| Return on average equity | -27.22% | -11.21% |
| Employees | 40 | - |
Address
12276 Wilkins Avenue
Rockville, MD 20852
United States - Map
+1-301-7703099 (Phone)
+1-301-7703097 (Fax)
Rockville, MD 20852
United States - Map
+1-301-7703099 (Phone)
+1-301-7703097 (Fax)
Website links
Company website:
http://www.nabi.com/
http://www.nabi.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Nabi Biopharmaceuticals discussed on blogs
Ranking All U.S. Stocks by Weekly Performance - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- 1 hour ago
Anti-Smoking Vaccine Is Nearing the Market · TechBlogger
- TechBlogger
- 18 hours ago
Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 20, 2009
Nabi Biopharmaceuticals discussions
View all discussions »Description
Nabi Biopharmaceuticals is a biopharmaceutical company focused on the development of products in the areas of nicotine addiction and infectious disease. The Company’s products in development are Nicotine Conjugate Vaccine (NicVAX) and Pentavalent S.aureus Vaccine (PentaStaph). NicVAX is an investigational vaccine. NicVAX is designed to stimulate the immune system to produce highly specific antibodies that bind to nicotine. PentaStaph is an investigational vaccine based on technology that it has licensed on an basis from the National Institutes of Health (NIH).
Officers and directors
| Raafat E.F. Fahim Ph.D. | President, Chief Executive Officer, Acting Chief Financial Officer, Director | |
| Paul Kessler M.D. | Senior Vice President - Clinical, Medical and Regulatory, Chief Medical Officer | |
| Geoffrey F. Cox Ph.D. | Non-Executive Chairman of the Board | |
| David L. Castaldi Ph.D. | Director | |
| Richard A. Harvey Jr. | Director | |
| Linda Jenckes | Director | |
| Stephen G. Sudovar | Director |